Waltham, MA – March 26, 2014 (Booth # 1343) – Corindus Vascular Robotics, the leader in precision vascular robotics, will showcase its FDA-cleared CorPath System at the upcoming American College of Cardiology (ACC) annual meeting, March 29 – 31 in Washington, D.C. The CorPath is the first medical device to bring robotic precision and accuracy to coronary angioplasty to help optimize clinical outcomes. Corindus representatives will be onsite to conduct demos of the CorPath System and answer questions about the significant advantages in procedure precision and improvements in clinical outcomes made possible by robotics in the cath lab.

Christiana Care Health System is one of a handful of institutions in the region to participate in ABSORB III, the first clinical trial in the United States of an absorbable vascular scaffold for patients with coronary artery disease.

The New York Times reports that nitroglycerine, the go-to drug in emergency rooms when physicians suspect an MI, may face intermittent shortages, according to its sole supplier.

Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC(tm)) technology for clinical diagnostics and scientific discovery, yesterday presented new data at the American Heart Association Epidemiology and Prevention Council Conference highlighting research results using the Company's proprietary ultrasensitive Erenna® Immunoassay System in the detection of cardiac troponin-I (cTnI). The study utilized the Erenna System to measure previously undetected increases in cTnI to predict development of coronary heart disease (CHD) in the general population, independent of a variety of traditional risk factors.

An interactive dance project called 4Chambers includes choreography that depicts a cardiac arrest and video about heart attacks. The work, described in Studio 360, was inspired by a conversation with a cardiologist who encourages her patients to dance, which she calls “the perfect activity.”  

Continuing to advance leading stent technology, Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the REBEL™ Platinum Chromium Coronary Stent System, the company's latest generation bare metal stent for the treatment of coronary artery disease (CAD).

Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics into personalized nutrition and lifestyle programs for patients with or at risk for heart disease, announced the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke.

An article by Bloomberg News claims that the cath lab at Mount Sinai Hospital in New York City has sent patients with previously scheduled appointments through its emergency department (ED), a practice that may allow for uninsured patients’ costs to be covered. The hospital has not been accused of any wrong-doing and hospital officials said they are reviewing issues related to the allegations.